Cargando…

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients

From March through August 2015, nearly 60 teams from around the world participated in the Prostate Cancer Dream Challenge (PCDC). Participating teams were faced with the task of developing prediction models for patient survival and treatment discontinuation using baseline clinical variables collecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Richard, Graw, Stefan, Usset, Joseph, Raghavan, Rama, Dai, Junqiang, Chalise, Prabhakar, Ellis, Shellie, Fridley, Brooke, Koestler, Devin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365222/
https://www.ncbi.nlm.nih.gov/pubmed/28413609
http://dx.doi.org/10.12688/f1000research.8226.1
_version_ 1782517478176325632
author Meier, Richard
Graw, Stefan
Usset, Joseph
Raghavan, Rama
Dai, Junqiang
Chalise, Prabhakar
Ellis, Shellie
Fridley, Brooke
Koestler, Devin
author_facet Meier, Richard
Graw, Stefan
Usset, Joseph
Raghavan, Rama
Dai, Junqiang
Chalise, Prabhakar
Ellis, Shellie
Fridley, Brooke
Koestler, Devin
author_sort Meier, Richard
collection PubMed
description From March through August 2015, nearly 60 teams from around the world participated in the Prostate Cancer Dream Challenge (PCDC). Participating teams were faced with the task of developing prediction models for patient survival and treatment discontinuation using baseline clinical variables collected on metastatic castrate-resistant prostate cancer (mCRPC) patients in the comparator arm of four phase III clinical trials. In total, over 2,000 mCRPC patients treated with first-line docetaxel comprised the training and testing data sets used in this challenge. In this paper we describe: (a) the sub-challenges comprising the PCDC, (b) the statistical metrics used to benchmark prediction performance, (c) our analytical approach, and finally (d) our team’s overall performance in this challenge. Specifically, we discuss our curated, ad-hoc, feature selection (CAFS) strategy for identifying clinically important risk-predictors, the ensemble-based Cox proportional hazards regression framework used in our final submission, and the adaptation of our modeling framework based on the results from the intermittent leaderboard rounds. Strong predictors of patient survival were successfully identified utilizing our model building approach. Several of the identified predictors were new features created by our team via strategically merging collections of weak predictors. In each of the three intermittent leaderboard rounds, our prediction models scored among the top four models across all participating teams and our final submission ranked 9 (th) place overall with an integrated area under the curve (iAUC) of 0.7711 computed in an independent test set. While the prediction performance of teams placing between 2 (nd)- 10 (th) (iAUC: 0.7710-0.7789) was better than the current gold-standard prediction model for prostate cancer survival, the top-performing team, FIMM-UTU significantly outperformed all other contestants with an iAUC of 0.7915.  In summary, our ensemble-based Cox regression framework with CAFS resulted in strong overall performance for predicting prostate cancer survival and represents a promising approach for future prediction problems.
format Online
Article
Text
id pubmed-5365222
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-53652222017-04-14 An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients Meier, Richard Graw, Stefan Usset, Joseph Raghavan, Rama Dai, Junqiang Chalise, Prabhakar Ellis, Shellie Fridley, Brooke Koestler, Devin F1000Res Method Article From March through August 2015, nearly 60 teams from around the world participated in the Prostate Cancer Dream Challenge (PCDC). Participating teams were faced with the task of developing prediction models for patient survival and treatment discontinuation using baseline clinical variables collected on metastatic castrate-resistant prostate cancer (mCRPC) patients in the comparator arm of four phase III clinical trials. In total, over 2,000 mCRPC patients treated with first-line docetaxel comprised the training and testing data sets used in this challenge. In this paper we describe: (a) the sub-challenges comprising the PCDC, (b) the statistical metrics used to benchmark prediction performance, (c) our analytical approach, and finally (d) our team’s overall performance in this challenge. Specifically, we discuss our curated, ad-hoc, feature selection (CAFS) strategy for identifying clinically important risk-predictors, the ensemble-based Cox proportional hazards regression framework used in our final submission, and the adaptation of our modeling framework based on the results from the intermittent leaderboard rounds. Strong predictors of patient survival were successfully identified utilizing our model building approach. Several of the identified predictors were new features created by our team via strategically merging collections of weak predictors. In each of the three intermittent leaderboard rounds, our prediction models scored among the top four models across all participating teams and our final submission ranked 9 (th) place overall with an integrated area under the curve (iAUC) of 0.7711 computed in an independent test set. While the prediction performance of teams placing between 2 (nd)- 10 (th) (iAUC: 0.7710-0.7789) was better than the current gold-standard prediction model for prostate cancer survival, the top-performing team, FIMM-UTU significantly outperformed all other contestants with an iAUC of 0.7915.  In summary, our ensemble-based Cox regression framework with CAFS resulted in strong overall performance for predicting prostate cancer survival and represents a promising approach for future prediction problems. F1000Research 2016-11-16 /pmc/articles/PMC5365222/ /pubmed/28413609 http://dx.doi.org/10.12688/f1000research.8226.1 Text en Copyright: © 2016 Meier R et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Method Article
Meier, Richard
Graw, Stefan
Usset, Joseph
Raghavan, Rama
Dai, Junqiang
Chalise, Prabhakar
Ellis, Shellie
Fridley, Brooke
Koestler, Devin
An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
title An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
title_full An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
title_fullStr An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
title_full_unstemmed An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
title_short An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
title_sort ensemble-based cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mcrpc) patients
topic Method Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365222/
https://www.ncbi.nlm.nih.gov/pubmed/28413609
http://dx.doi.org/10.12688/f1000research.8226.1
work_keys_str_mv AT meierrichard anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT grawstefan anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT ussetjoseph anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT raghavanrama anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT daijunqiang anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT chaliseprabhakar anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT ellisshellie anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT fridleybrooke anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT koestlerdevin anensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT meierrichard ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT grawstefan ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT ussetjoseph ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT raghavanrama ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT daijunqiang ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT chaliseprabhakar ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT ellisshellie ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT fridleybrooke ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients
AT koestlerdevin ensemblebasedcoxproportionalhazardsregressionframeworkforpredictingsurvivalinmetastaticcastrationresistantprostatecancermcrpcpatients